Canada's Drug Agency Recommends Public Reimbursement for Leqembi
Canada's Drug Agency (CDA-AMC) has issued a final recommendation supporting public reimbursement for Leqembi (lecanemab). The recommendation is for eligible patients in Canada diagnosed with mild cognitive impairment.
Canada's Drug Agency (CDA-AMC) has issued a final positive recommendation supporting public reimbursement for Leqembi (lecanemab). This recommendation facilitates access to the Alzheimer's disease treatment for eligible patients across Canada.
The decision, announced by BioArctic AB's partner Eisai, means that the drug can now be considered for public funding for patients meeting specific clinical criteria. Leqembi targets the underlying pathology of Alzheimer's disease by removing amyloid plaques from the brain.
Clinical trials have demonstrated Leqembi's ability to slow cognitive decline in individuals with early-stage Alzheimer's. This recommendation is based on the evidence presented regarding the drug's efficacy and safety profile.
The final recommendation by CDA-AMC is a significant development for Alzheimer's treatment access in Canada and follows previous reviews of the therapy's clinical data.